Navigation Links
Rhode Island Biotechnology Company Develops Tularemia Vaccine

EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has developed a promising tularemia vaccine // candidate (TuliVaxTM) that confers protective immunity. Francisella tularensis is a bacterium considered to be one of the most dangerous potential bioterror agents.

This vaccine project was funded by a BioDefense Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The animal studies, conducted at Rhode Island Hospital, showed that TuliVaxTM protected mice from lethal bacterial challenge.

“Our unique ability to develop safe and effective vaccines by screening whole genomes for candidate vaccine components with computer algorithms is at the core of this research effort,” said Anne De Groot, M.D., President and CEO of EpiVax. “These study results highlight the ability of our computer-aided vaccine design (VaccineCAD) approach to create effective and innovative vaccines at an accelerated pace”.

Tularemia is rare but does occur naturally; the most lethal pulmonary form is more common in Martha’s Vineyard than in most other places in the world. EpiVax collaborated with Martha’s Vineyard Hospital to obtain bloods from people with previous tularemia infection; 95% of the study participants demonstrated robust responses to the TuliVaxTM components.

Mice with “humanized” immune systems were used by Rhode Island Hospital collaborator Stephen Gregory PhD, Associate Professor of Medicine, Department of Medicine, Rhode Island Hospital and Brown Medical School, to assess the ability of the vaccine to protect against a lethal dose of F. tularensis. Although all of the mice that received a placebo vaccine died when exposed to tularemia, the majority of the mice that received TuliVaxTM survived.

The development of a safe and effective tularemia vaccine has proven elusive; the live vaccine str ain (LVS) of tularensis was the major tularemia vaccine under study for many years. Although it conferred partial protection, federal funding to license LVS has been cancelled due to safety and manufacturing concerns1.

“There is an urgent need for a safe, effective tularemia vaccine to address both natural infections and potential biothreats. TuliVax is likely to be safe because it is composed of small synthetic parts, not the live bacterium”, says Dr. Gregory. “Preliminary results in mice are encouraging; additional experiments are required to provide the data needed for TuliVax to progress to human clinical trials.”



Source-Bio-Bio Technoogy
SRI
'"/>




Related medicine news :

1. Rhode Island legalizes use and possession of Marijuana
2. Meningitis Scare Keeps Children At Home In Rhode Island
3. Rhode Island legalizes use and possession of Marijuana
4. Chikungunya Epidemic On French Island Claims 52 lives
5. French Minister To Visit La Reunion Island To Monitor Chikungunya Epidemic
6. Phoenix Islands To Be Protected Under Global Conservation Map
7. Assams Floating Hospital To Render Medical Services To Islanders
8. Reports Of A HIV Break Out Scare People Of A Holiday Island
9. King Island Water Certified Potable
10. E. coli causes havoc in Fire Island
11. Meningitis Scare Keeps Children At Home In Rhode Island
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: